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Abstract
Introduction: The 2015 WHO recommendation of antiretroviral therapy (ART) for all HIV-positive persons calls for treatment
initiation in millions of persons newly eligible with high CD4+ counts. Efficient and effective care models are urgently needed
for this population. We evaluated clinical outcomes of asymptomatic HIV-positive adults and children starting ART with high
CD4+ counts using a novel streamlined care model in rural Uganda and Kenya.
Methods: In the 16 intervention communities of the HIV test-and-treat Sustainable East Africa Research for Community
Health Study (NCT01864603), all HIV-positive individuals irrespective of CD4 were offered ART (efavirenz [EFV]/tenofovir
disoproxil fumarate + emtricitabine (FTC) or lamivudine (3TC). We studied adults (≥fifteen years) with CD4 ≥ 350/μL and
children (two to fourteen years) with CD4 > 500/μL otherwise ineligible for ART by country guidelines. Clinics implemented a
patient-centred streamlined care model designed to reduce patient-level barriers and maximize health system efficiency. It
included (1) nurse-conducted visits with physician referral of complex cases, (2) multi-disease chronic care (including for
hypertension/diabetes), (3) patient-centred, friendly staff, (4) viral load (VL) testing and counselling, (5) three-month return
visits and ART refills, (6) appointment reminders, (7) tiered tracking for missed appointments, (8) flexible clinic hours (outside
routine schedule) and (9) telephone access to clinicians. Primary outcomes were 48-week retention in care, viral suppression
(% with measured week 48 VL ≤ 500 copies/mL) and adverse events.
Results: Overall, 972 HIV-positive adults with CD4+ ≥ 350/μL initiated ART with streamlined care. Patients were 66% female
and had median age thirty-four years (IQR, 28–42), CD4+ 608/μL (IQR, 487–788/μL) and VL 6775 copies/mL (IQR, <500–
37,003 c/mL). At week 48, retention was 92% (897/972; 2 died/40 moved/8 withdrew/4 transferred care/21/964 [2%] were
lost to follow-up). Viral suppression occurred in 778/838 (93%) and 800/972 (82%) in intention-to-treat analysis. Grade III/IV
clinical/laboratory adverse events were rare: 95 occurred in 74/972 patients (7.6%). Only 8/972 adults (0.8%) switched ART
from EFV to lopinavir (LPV) (n = 2 for dizziness, n = 2 for gynaecomastia, n = 4 for other reasons). Among 83 children, week
48 retention was 89% (74/83), viral suppression was 92% (65/71) and grade III/IV adverse events occurred in 4/83 (4.8%).
Conclusions: Using a streamlined care model, viral suppression, retention and ART safety were high among asymptomatic
East African adults and children with high CD4+ counts initiating treatment.
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Introduction
Global guidelines now endorse antiretroviral therapy (ART)
for all HIV-infected individuals [1] to improve broad clinical
outcomes [2,3], reduce transmission [4] and aggressively
impact the course of the HIV epidemic [5]. An estimated 16
million persons are now on ART worldwide [6], but much
greater ART access, centred in sub-Saharan Africa, needs to
be achieved to reach global goals [7]. This urgent need to
expand ART delivery occurs at a time of global resource
constraints [8], making it imperative that we design, test
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and implement highly efficient and effective models of care
for ART delivery.
As ART access and availability expand, large numbers of
patients previously ineligible for therapy – particularly
patients with high CD4+ T-cell counts and asymptomatic
disease – are entering care. Older models of care designed
during the AIDS emergency response over a decade ago are
not optimally efficient for either patients or the health
system. Until recently, most care delivery systems have
offered “one-size-fits-all” approaches with similar services
for both sicker and healthier patients. These models do not
capitalize on the fact that healthier patients with high CD4+
counts above 350 cells/μL can be served with streamlined
care systems that may be more effective for the patient
and highly efficient for the health system [9].
A large and growing body of literature has evaluated many
single-component interventions designed to improve clinic
efficiency and offer “differentiated care” interventions includ-
ing pharmacy refill programmes [10,11], nurse-driven triage
systems [12–14], mobile phone outreach [15–17] and com-
munity navigation services [18,19]. However, literature on
combination interventions – packages of interventions that
together comprise a system of care delivery – is limited.
Our group previously tested a streamlined ART delivery
system in a single Ugandan clinic and demonstrated strong
retention in care and viral suppression among patients with
CD4+ counts above Ugandan guideline threshold
(CD4 > 350) [20]. This model was adapted as part of the
intervention in the SEARCH Study (Sustainable East Africa
Research for Community Health: NCT01864603), a large-
scale HIV test-and-treat study assessing whether a strategy
of universal HIV testing and ART delivery lowers HIV inci-
dence and improves health outcomes. In this report, we
evaluate one-year outcomes of retention, viral suppression
and safety of our streamlined care model across a series of
rural communities in Uganda and Kenya.
Methods
Ethics statement
This study was approved by ethical review boards of
Makerere University, Uganda National Council of Science
and Technology (Kampala, Uganda), Kenya Medical
Research Institute (Nairobi, Kenya) and the University of
California, San Francisco (USA). Participants were consented
for study participation.
Study setting
This is a 48-week analysis of clinical and virologic outcomes
of Ugandan and Kenyan HIV-infected adults (age ≥ fifteen
years) and children (age two to fourteen years) with high
CD4+ cell counts, not qualifying for ART by current country
guidelines, who received ART using a patient-centred
streamlined model of care.
The SEARCH Study is an ongoing community cluster
randomized trial of a universal HIV “test-and-treat” strat-
egy in 32 rural Ugandan and Kenyan communities
(NCT01864683). In 16 SEARCH intervention communities,
all community members (adults and children) were
offered annual HIV testing via community health fairs.
Health fair non-attendees received home visits during
which HIV testing was offered [21]. Point-of-care CD4+
cell counts were determined in all HIV-positive persons
(PIMA, Alere). Participants, upon HIV diagnosis at a com-
munity health fair or during in-home testing, were imme-
diately given appointments at the local clinic for
immediate evaluation in <1 week for ART initiation.
Pregnant women and persons with CD4 < 200/μL received
appointment dates within 2 days. Adult patients or guar-
dians of paediatric patients were given the clinic’s mobile
phone number and encouraged to call with questions
about appointments, symptoms or any other reason.
This phone was staffed 24 h/day. Patients were also
offered a single small transport reimbursement upon pre-
sentation to the first clinic visit.
ART initiation and monitoring
In clinics, ART eligibility was first assessed using Uganda-
and Kenya-specific guidelines between June 2013 and June
2014. In both countries, at the start of study, persons were
eligible for ART if a WHO Stage 3 or 4 condition was
diagnosed, if CD4+ count was <350/μL, or if CD4 > 350
and patient had (1) tuberculosis, (2) hepatitis B virus infec-
tion or (3) pregnancy. Individuals meeting country ART
initiation guidelines received medications through the exist-
ing government-sponsored programme. Patients ineligible
for ART by country guidelines were offered participation
under informed consent described here. For children,
informed consent was obtained from a legal guardian.
ART was provided by the study. For adults, this
included efavirenz (EFV) plus tenofovir disoproxil fuma-
rate (TDF) co-formulated either with emtricitabine (i.e.
FTC/TDF, Truvada) or with lamivudine (i.e. FTC/3TC), con-
sistent with national guidelines. For children, ART
included abacavir/3TC with either EFV or nevirapine, or
alternately, TDF with either FTC or 3TC, consistent with
national guidelines. Following ART initiation, adult and
child participants had clinic visits at weeks 0, 4, 12, 24,
36 and 48. Safety laboratory monitoring (creatinine,
aspartate and alanine transferase and haemoglobin) was
performed at 24 and 48 weeks and results graded by the
DAIDS laboratory adverse event scale [22]. Clinicians
asked patients about adverse symptoms or clinical events
since their last visit; they also recorded events volun-
teered by participants at regularly scheduled or off-sche-
dule visits.
Patient-centred streamlined care model for clinics
Part of the SEARCH Study HIV test-and-treat intervention
strategy is a multicomponent streamlined ART delivery
model (Table 1). This streamlined care model is designed
around three central principles: (1) reducing structural bar-
riers to care, (2) improving relationships between patients
and the clinic and (3) enhancing patient and clinician knowl-
edge of HIV and ART.
Upon linkage to the clinic, adult and paediatric partici-
pants received care in the streamlined care model. This
model was designed to reduce clinic inefficiencies that
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arise when staffing and services needed for HIV-positive
patients with symptomatic, complex HIV disease are
applied uniformly to patients with early stage, asympto-
matic HIV disease. In our clinics, HIV care was part of a
chronic disease care model offering joint evaluation and
management of hypertension, diabetes and general medi-
cal conditions. All patients receiving HIV care, hyperten-
sion/diabetes and medical care were served with identical
processes.
Structural barriers to care were targeted in several ways.
First, our streamlined care model used a nurse-driven triage
and care system (Table 1) that aimed to reduce wait times
by fostering rapid, focused clinic visits. Nurses evaluated
patients for ART side effects, assessed ART adherence and,
if needed, consulted with a physician for advice.
Periodically, nurses also dispensed ART and performed
phlebotomy while at other times, patients received ART at
the clinic pharmacy and saw a phlebotomist. Wait times
were decreased by giving patients three-month ART refills
rather than standard one- or two-month refills. Second, we
aimed to reduce opportunity costs (e.g. missing work and
transportation costs) to patients for attending clinic visits in
two ways. Our clinical model offered multi-disease services
including HIV, hypertension and diabetes care. We
hypothesized that this could allow patients with multiple
diagnoses to receive services for multiple conditions effi-
ciently, rather than in separate visits, reducing transporta-
tion and opportunity costs of time away from work.
Additionally, longer three-month ART refills were designed
to reduce opportunity costs of making clinic visits. Third,
our streamlined care model aimed to improve convenience
for patients. Patients were offered the clinic’s mobile
phone number and encouraged to call for appointment
rescheduling or to clarify appointment dates in order to
avoid missed visits. Appointment reminder phone calls
were made to all patients 1 week prior to appointments.
Further, patients expressing difficulty attending clinic visits
during normal operating hours were accommodated with
off-hours visits as needed. Finally, patients who missed
visits received a tiered series of re-engagement interven-
tions, including a phone contact, home visit and facilitated
transport to return to clinic.
Improved relationships between patients and clinics
were prioritized in several ways (Table 1). Clinic staff
received training in methods of fostering a friendly and
patient-centred atmosphere in clinic, and during all com-
munications via the phone hotline. Training consisted of
role-play scenarios and didactic lectures and was augmen-
ted with monthly team meetings to discuss challenging
situations and share “success stories” recorded by staff in
diaries. Further, the care model also featured appointment
reminder phone calls and access to a clinic phone hotline
for questions, both of which we hypothesized would
strengthen patients’ feeling of connection and caring from
the clinic.
Finally, our streamlined care model aimed to improve
both clinicians’ and patients’ knowledge of ART and HIV
disease so that patient motivation to attend visits would be
higher, and stigma experienced by patients in coming to
clinic would be reduced (Table 1). We performed viral load
(VL) testing and provided interpretation of results and
structured counselling to all patients. Clinic staff received
training on VL counselling methods, using scripts containing
scenarios of both viral suppression and non-suppression to
enhance their knowledge of HIV disease and the effects of
ART. Clinician training emphasized methods to transmit this
knowledge directly to patients to increase their understand-
ing of both HIV and ART, and to promote motivation and
Table 1. Features of streamlined care designed to improve visit attendance, ART adherence and clinic efficiency.
Reduced structural barriers
to care
Improved relationship
with clinic Enhanced attitudes and knowledge
Waiting
time Cost Convenience
Direct
access to
clinicians
Respectful
interactions
Improve
motivation
Improve HIV
and ART
knowledge
Reduce
stigma
HIV care delivery and retention
Nurse triage and care •
Three month visit for stable patients • • • •
Multi-disease chronic care model • • • •
Friendly clinic staff • • •
Appointment reminders • •
Tiered tracking for clinic no-show • •
Viral load counselling •
Flexible clinic hours • • • • •
Phone access to clinic providerA • • • • • • • •
AProvided for questions related to symptoms/clinical problems, ART, scheduling or logistics of appointments or other concerns. • Indicates
that the streamlined care intervention targets the area for clinical operations improvement.
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ART adherence. Telephone access, noted above, was also
hypothesized as a vehicle for clinicians to educate patients
on HIV and ART topics. Lastly, the streamlined care model
was designed to reduce stigma in two central ways. First, by
co-locating HIV services with hypertension, diabetes and
other services, we sought to mitigate stigma that could be
attached to attending a clinic known primarily for HIV
services (i.e. “HIV clinic”). Second, as noted, the patient-
centred and friendly clinic atmosphere was designed to
avoid negative, judgmental or adverse clinician–patient
interactions that are a known cause of stigma.
Supplementary Appendix A summarizes features of the
SEARCH streamlined care model, with contrast to features
of the care model in use in SEARCH Study clinics prior to
initiation of the study. Paediatric-specific adaptations to the
streamlined care model are also described (Supplementary
Appendix A).
Study outcomes
We report clinical and laboratory outcomes among these
cohorts of adults receiving ART through streamlined care.
Retention in care was measured as the per cent of partici-
pants attending clinic visits at 12, 24 and 48 weeks, and loss
to follow-up was defined as a patient who missed a visit
and subsequently did not reappear. The virologic outcome
of the study was HIV RNA suppression, defined as the per
cent of participants with VL < 500 copies/mL at week 48.
ART safety outcomes were assessed as the per cent of
participants with grade III/IV clinical or laboratory adverse
events (DAIDS scale) [22]. To assess utilization of the non-
communicable disease services offered in our streamlined
care model in the Uganda clinics, we determined the pro-
portion of adult patients who had a visit for either diabetes
or hypertension care. On enrolment in the study, patients
were given a phone number to contact a clinician and told
they could call 24 h per day for any problem, question or
concern. A staff clinician from each clinic held this phone,
responded to calls promptly and recorded, for each call, the
identity of the caller, the time of the call, the total duration
of the call, the reason(s) for the call and their response
actions to the call. To assess utilization of the clinician
access telephone hotline, we tabulated in the Uganda
clinics the numbers of phone calls received, and for each
call, the time of day, duration, reason for call and what
actions clinicians took in response to the call.
Results
Baseline characteristics of adults and children
Overall, 972 adults with CD4 ≥ 350/μL and who were
ineligible for government-provided therapy initiated ART
(n = 411 [West Uganda], n = 99 [East Uganda] and
n = 462 [Kenya]; Table 2). Median age was thirty-four
years (IQR, 28–42), 66% of participants were female, 56%
worked in farming/agriculture and 13% had higher than
primary education. Median baseline CD4+ count was 608/
μL (IQR, 487–788/μL), and median baseline VL was
6775 copies/mL (IQR, <500–37,003; Table 2).
A total of 83 children with CD4 ≥ 500/μL who were
ineligible for government-provided therapy initiated ART
(n = 26 [West Uganda], n = 11 [East Uganda] and n = 46
[Kenya]; Table 2). Median age was eight years (IQR, 6–11),
57% were female and 29/83 (35%) were orphaned. Median
baseline CD4+ count was 863/μL (IQR, 662–1180/μL), and
median baseline VL was 23,343 c/mL (IQR, 8644–98,613;
Table 2).
Adult retention in care and virologic suppression
Of the 972 adults who initiated ART, 897/972 were retained in
care at week 48 (92%; Figure 1). The most common reasons
for non-retention included moving away from study region
(n = 30) and becoming lost to follow-up (n = 33). Retention
patterns (i.e. retention rates at 12, 24 and 48 weeks) were
similar in adults who initiated ART at CD4+ 350–500/μL versus
>500/μL (Figure 2). Of 897 adults retained at week 48, 838/
897 (93%) had a VL measurement available for analysis. Of
these, VL was undetectable in 778/838 (93%; Table 3). We
performed an intention-to-treat (ITT) analysis that considered
adults not retained at week 48 (n = 75), as well as adults
retained at week 48 but without VL measured (n = 30), to be
virologically detectable. Adults retained at week 48 lacking VL
s but who subsequently had a VL ascertained (n = 29) had
virologic suppression assessed using the post-week 48 VL.
Viral suppression in this ITT analysis showed 800/972 (82%)
participants with viral suppression.
Adult adverse events
Overall, grade III/IV clinical and laboratory adverse events
were rare. Among adults, 95 adverse events occurred in 74/
972 (7.6%) of patients. The most common clinical adverse
events were fever (n = 5 [malaria, n = 4, pneumonia, n = 1],
all resolved) and dizziness (n = 2; related to EFV initiation,
both resolved). The most common laboratory adverse event
was neutropenia (n = 16, all asymptomatic and not asso-
ciated with fever). Two patients died during the first
48 weeks on ART, one due to alcohol poisoning, and the
other from causes we were not able to ascertain. Of the 74
patients who had either a clinical or laboratory event, the
median CD4+ count at ART initiation was 711 cells/μL (IQR,
499–838 cells/μL). Alterations to ART medications were rare:
overall, only 8/972 patients (0.8%) of patients switched from
first-line EFV-based ART to second-line ritonavir/lopinavir-
based ART. Reasons for ART switches included dizziness
(n = 2), gynaecomastia (n = 2) and other (n = 4).
Streamlined care parameters
A total of 26/510 (5.1%) of adult patients in Uganda study
clinics received care that included both HIV services and
services for non-communicable diseases (either hypertension
or diabetes). Overall, clinicians in the 10 Uganda clinics
received a total of 183 telephone calls from 510 patients in
the first year after ART initiation (Supplementary Appendix B).
In 84%, the caller was the patient; 9% of the time, the caller
was a family member. Most calls occurred during normal
business hours 9am–5pm (103/183, 56%), and only 7%
occurred overnight (13/183). Most calls were 1–5 min in
duration (127/183, 69%). Top reasons for calls included
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requests to clarify appointment dates (24% of calls), discus-
sion of a perceived ART side effect (15%) and discussion of a
non-urgent health problem (11%). Most frequent responses
by clinicians included general counselling (24% of calls), clar-
ification (22%), rescheduling (15%) or moving up (8%) of
appointment dates, or other responses [mostly discussion or
clarification of appointment dates or test results
(Supplementary Appendix B)].
Paediatric retention in care, virologic suppression and
adverse events
As shown in Figure 3, 83 children (two to fourteen years) who
did not meet in-country criteria to start ART and who had
CD4 ≥ 500/μL initiated ART. ART regimens included (1)
ABC + 3TC + EFV (n = 62/83 [74.7%]), (2) ABC + 3TC + NVP
(n = 4/83 [4.8%]) and (3) TDF + (3TC or FTC) + EFV (n = 17
[20.5%]). Retention in care at week 48 was 89% (74/83;
Figure 2): four children moved away, one withdrew consent,
one declined medications and three had non-ascertained rea-
sons for being lost to follow-up (Figure 3). Of 74 children
retained at week 48, 71/74 (96%) had a measured VL, and
virologic suppression was 92% (65/71; Table 3). Adverse events
were uncommon: only 3/83 children (3.6%) had a clinical or
laboratory adverse event of grade III/IV. Events were neutro-
penia (n = 1), thrombocytopenia (n = 1) and rash (n = 1). Two
changes in ART occurred: nevirapine was stopped due to a
grade IV hypersensitivity rash, and abacavir was stopped due
to a grade II rash in ART regimen.
Discussion
In a network of government-sponsored rural Ugandan and
Kenyan healthcare clinics within the SEARCH Study, we
assessed the effectiveness of a patient-centred streamlined
care delivery model for adults and paediatric patients with
high CD4+ counts. We found excellent rates of retention in
care, virologic suppression and low rates of toxicity in bothTa
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Figure 1. CONSORT diagram for adult participants. Analysis of
972 HIV-positive adults (age ≥ 15) with CD4+ count ≥350/μL who
initiated ART.
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adult and paediatric patient groups. Our data represent one
of the largest reports of a multicomponent streamlined
care system designed for individuals with high CD4+ counts
– a patient population whose numbers are growing in the
current universal ART era, and who are likely to be the
most amenable to streamlined efficient care systems.
The high rate of retention in care we observed may be
partly attributable to our streamlined care system addres-
sing three key domains that literature has shown to predict
retention failures: (1) structural barriers, (2) suboptimal
patient–clinician relationships and (3) gaps in patient and
clinician knowledge that lead to stigma and motivation
problems. First, structural barriers to care (e.g. long wait
times, frequent visits, opportunity costs to work and incon-
venience) have been repeatedly demonstrated to degrade
retention in care [23–26]. Our streamlined care system
aimed to reduce wait times using a nurse-driven rapid
process focusing on basic ART toxicity screening [20,27].
We previously reported that visit lengths for streamlined
care patients (including pre-visit wait time) were 68 min on
average, compared to 155 min for non-streamlined care.
Figure 2. Retention in care at weeks 12, 24 and 48 following ART initiation among adults with CD4+ count 350–500/μL (dark grey), adults
with CD4+ >500/μL (medium grey), all adults regardless of CD4+ count (light grey) and children (age < 15, CD4+ ≥500/μL; white), with 95%
confidence intervals (black error bars).
Table 3. HIV RNA suppression in adults (n = 838) and children (n = 71) 48 weeks after initiating antiretroviral therapy at high CD4
+ counts
Adults (≥fifteen years) Children (two to fourteen years)
CD4+ 350–500/μL (n = 232) CD4+ >500/μL (n = 606) All Adults (n = 838) CD4+ >500/μL (n = 71)
HIV RNA (copies/mL) N % N % N % N %
<500 218 94.0 560 92.4 778 92.8 65 91.5
500–10,000 7 3.0 20 3.3 27 3.2 4 5.6
10,001–100,000 6 2.6 20 3.3 26 3.1 2 2.8
>100,000 1 0.4 6 1.0 7 0.8 0 0.0
Figure 3. CONSORT diagram for paediatric participants. Analysis
of 83 HIV-positive children (age < 15) with CD4+ count ≥500/μL
who initiated ART.
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This was due both to longer waits before and during visits
[27]. Our streamlined care system also aimed to reduce visit
frequency both by allowing longer three-month ART refills
(vs. typical one to two month refills in Uganda and Kenya),
as well as by combining healthcare provision for HIV, hyper-
tension and diabetes into single visits when applicable.
Second, patient perceptions of mistreatment by clinicians
have also been clearly linked to retention in care failures
[25,26]. Patients cite judgmental, negative interactions with
clinicians during discussions of adherence, ART use, missed
visits or gaps in care. Our streamlined care system thus
aimed to formally train clinicians in providing friendly, wel-
coming care using supportive, encouraging interactions
revolving around patients’ desires for their care. This was
especially important when clinicians faced challenging
situations of incomplete ART adherence or missed visits.
We also incorporated regular team discussions for clinicians
to share challenges and successes – a feedback process that
may have helped sustain a positive environment. Literature
on promoting patient-centred care supports the concept
that such practice can be taught [28], promotes clinician
job satisfaction and reduces burnout that lowers quality of
care over time [29].
Third, improvements in retention in care have been
linked to increased knowledge and understanding of HIV
disease and ART [30]. More broadly, the importance of
patient knowledge and health literacy has gained attention
as a crucial factor for durable retention in care – an out-
come that depends on patients building self-efficacy, and
feeling knowledgeable enough to participate in shared deci-
sion-making [31]. In addition, stigma is well established in
the literature as a persistent threat to retention in care
[25]. Our streamlined care system attempted to reduce
stigma by embedding HIV care within a broader streamlined
general medical care system, offering hypertension, dia-
betes and other care in parallel with HIV care. This may
have allowed patients to visit the clinic without the reason
being apparent to others (i.e. because all services [both
HIV-related and non-HIV-related] were delivered jointly).
Further, by labelling our clinics as “medical” rather than
“HIV” clinics, stigma may have been further reduced. Lastly,
since HIV-positive patients often have longer visits than
patients receiving non-HIV-related care, our short visit
times – on average 30 min [20,27] – may have eliminated
this differentiating factor that could identify patients’ HIV
diagnoses. In our view, the streamlined care components
that impacted outcomes most strongly were the rapid visit
procedures that resulted in <30 min visits, combined with
long three-month ART refills (both of which lowered oppor-
tunity costs for attending clinic visits), as well as the
patient-centred environment and direct discussions of VL
results. Qualitative analyses of our patients’ perceptions on
structural barriers, patient–clinician relationships and moti-
vation and stigma are already underway and will help
determine which features of streamlined care were most
effective.
We observed high rates of viral suppression, consistent
with a growing literature showing positive outcomes in ART
patients, including those with high CD4+ T cell counts
>350–500/μL [2–4]. Recent population-based cohorts have
shown high viral suppression among adults with lower CD4
+ counts receiving ART under standard, non-streamlined/
differentiated care models. Viral suppression has been
reported from cohorts in Nigeria (85% with VL ≤ 400 c/
mL) [32], Malawi (91% with VL ≤ 1000 c/mL) [33] and Kenya
(84% with VL ≤ 1000 c/mL) [34]. In addition, our group
reported an 82% viral suppression (VL ≤ 500 c/mL) in the
large rural Ugandan and Kenyan populations comprising the
SEARCH Study baseline population [35]. Thus, although we
cannot attribute a causal link between our streamlined care
intervention and our one-year results in this report, our
viral suppression rates among patients with high CD4+
counts are similar to or exceed those seen in lower CD4+
count patients, most of whom did not receive streamlined/
differentiated care.
Our structured VL counselling may have influenced our
positive results: we shared VL values with patients using a
system that emphasized knowledge and linkages between
ART adherence and VL results. We observed that sharing
undetectable VL results allowed reinforcement of patients’
good adherence patterns. We also found that numerically
demonstrating detectable viremia was a powerful tool for
building patients’ knowledge, promoting better adherence
and sustaining adherence over time. As VL access continues
to expand, coupling testing with structured counselling will
be key to maximizing its impact.
The HIV-infected children in this study achieved excellent
48-week retention (89%) and virologic suppression (92%)
rates compared to other reports from African settings. In
one study of 4803 South African children, 66% of children
receiving a community-based intervention for ART support
were virally suppressed compared to 55% receiving stan-
dard of care [36]. In cross-sectional data from programmes
in Swaziland, 71% of children <ten years old were virologi-
cally suppressed [37]. HIV-infected children and their guar-
dians receiving care in rural clinics face many of the same
barriers as adults that were targeted by our streamlined
care model (i.e. structural barriers, challenging clinician–
patient relationships and knowledge gaps enabling stigma
and motivation problems). However, HIV-infected children
face additional systems-level challenges, including the com-
plexity of weight-based ART dosing and shifting age- and
CD4-specific ART-initiation thresholds [38]. For this reason,
centres with paediatric HIV specialization are often devel-
oped in high prevalence urban areas. However, our results
suggest that as universal ART programmes continue to
decentralize and expand to rural populations, excellent out-
comes can be achieved by integrating paediatric HIV care
with adult programmes using streamlined care models like
that employed by SEARCH.
Key considerations during adoption of streamlined care
models include their costs, and the potential opportunities
and challenges in their scale up throughout sub-Saharan
Africa [39]. We recently estimated costs of our streamlined
care model to be $275 per person per year of ART delivery
[27], placing it in line with or less expensive than other care
models, some of which do not include VL testing and
counselling. These costs may decrease over time as ART
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costs are further optimized, and as VL testing grows and
achieves greater economy of scale. Challenges to scaling up
streamlined care may include barriers in rapidly shifting the
public health-centred model of clinic care to a truly patient-
centred paradigm, the need to secure excellent training and
mentoring for clinicians at all levels, instituting methods of
real-time tracking of the quality of care and providing
meaningful feedback within health systems and securing
durable funding for the continued expansion of VL testing.
However, opportunities to use the platform of HIV care
delivery to improve service delivery for a variety of other
medical conditions are now being captured at an increasing
rate. Streamlined care models designed to prioritize
patients’ experience and deliver broad health outcomes
have great potential to accelerate this progress.
Our study was subject to several limitations. First, we were
not able to ascertain VL results on all participants; however, as
our intention-to-treat analysis showed, viral suppression
remained high after conservatively accounting for these miss-
ing values. Second, because we delivered patient-centred
streamlined care as a multicomponent package intervention,
we could not assess which specific components of the stream-
lined care system are the most central to its overall success.
However, since most of our streamlined care components are
low cost (or even cost negative, as with providing longer ART
refills that lengthen visit intervals and reduce daily patient
loads), deploying streamlined care as a package may be com-
pelling at a public health level. Such packages could be custo-
mized to maximize effectiveness in different care settings
where varying components play different roles in achieving
retention in care and viral suppression. Qualitative analyses
are underway to assess patient and clinician perspectives on
elements of streamlined care and reasons for success. Third,
the use of mobile phone communication, both outgoing (for
appointment reminder calls) and incoming (providing tele-
phone access to patients), relies on patients having reliable
access to amobile phone. Thismay limit generalizability of our
results to unselected patient groups. However, mobile phone
use is expanding rapidly in both Uganda and Kenya [40,41],
and mobile phone-based interventions are gaining traction as
inexpensive and easy ways to deliver interventions [15,42],
including to children and adolescents [43]. Finally, the limited
numbers of paediatric patients in our analysis limit the preci-
sion of our estimates of viral suppression, and their general-
izability to other sub-Saharan African settings.
Conclusions
In a network of prototypic healthcare clinics in rural Ugandan
and Kenyan communities, we demonstrate excellent reten-
tion in care, viral suppression and low rates of adverse events
among HIV-positive adults and children with high CD4+ counts
receiving ART via a streamlined care delivery system. Our
results amplify growing evidence that streamlined care mod-
els, integrating paediatric and adult care in rural clinics, can
boost the efficiency of the healthcare delivery system while
also becoming more patient centred. Such efforts will be
central to meeting global goals of universal ART coverage for
all HIV-positive individuals in the coming years.
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